The Frequency, Causes and Risk Factors of Discontinuation of Dopamine Agonists in Parkinson’s Disease Patients
Objective: To determine the incidence, causes and risk factors of dopamine agonists (pramipexole and ropinirole) discontinuation in Parkinson’s disease patients. Background: Ropinirole and pramipexole are…Reviewing the clinical and mutational spectrum of SLC20A2, PDGFB, PDGFRB, XPR1 and MYORG mutations in Primary Familial Brain Calcification (PFBC) for MDSGene
Objective: We present the clinical and mutational spectrum of SLC20A2, PDGFB, PDGFRB, XPR1, and MYORG mutations, thereby adding a new gene, MYORG, recently found to…The PLA2G6 Gene Mutation Causes Parkinson’s Disease: A Case Report
Objective: To investigate the clinical features of Parkinson's disease caused by PLA2G6 gene mutation． Background: Early-onset Parkinsonism is a group of syndromes characterized by Parkinson's disease…Genetic markers revealed in dysregulated pathways in ischemic stroke may lead to Parkinson’s disease
Objective: To assess differential expression and gene set enrichment analysis to identify biological pathways associated with stroke and Parkinson’s disease (PD). Further, putative drug targets…X-chromosomal Dystonia-Parkinsonism: a systematic review of published and unpublished clinical data
Objective: To summarize and curate all published clinical data on x-chromosomal dystonia-parkinsonism (XDP) patients; identify relevant researches working on XDP and contact them for additional…People with Parkinson’s Disease (PPD): disease, stigma and the others
Objective: To show what does it mean to be PPD and the relationship with their environment from the point of view of the participants. Background:…Stigma in Egyptian patients with Parkinson’s disease
Objective: In this study we aimed to investigate stigma in Egyptian Parkinson’s disease patients using a culturally adapted Arabic version of the 39-item Parkinson's disease…Parkinson´s Disease, respiratory capacity and functionality: a Physical Therapy perspective
Objective: To correlate respiratory capacity with physical function in elderly patients with Parkinson's disease (PD). Background: As occurs in other neurodegenerative diseases, it is necessary…Use of syringe driver in End of Life Care in Parkinson’s Disease (PD)
Objective: To evaluate our current practice in the use of syringe drivers in End of Life Care in Parkinson’s Disease. Background: Palliative care in advanced…Patient organisation collaboration to advance patient engagement in Parkinson’s research
Objective: Developing a model for international collaboration on patient engagement with patient organisations and industry. Background: Involving people affected by health conditions in research is…
- « Previous Page
- 1
- …
- 176
- 177
- 178
- 179
- 180
- …
- 388
- Next Page »